Trial Profile
The efficacy of febuxostat or topiroxostat on nephropathy in type 2 diabetes with hyperuricemia: A randomized clinical trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2020
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Topiroxostat (Primary)
- Indications Diabetic nephropathies; Hyperuricaemia
- Focus Therapeutic Use
- 27 Sep 2020 Status changed from recruiting to discontinued.
- 16 Mar 2018 New trial record